Summary
This phase 3 randomised controlled trial investigated whether ramucirumab, a vascular endothelial growth factor receptor 2 antagonist, combined with docetaxel improved outcomes in patients with platinum-refractory advanced urothelial carcinoma. The trial enrolled participants across multiple centres internationally and measured survival, tumour response, and safety outcomes. Results would inform treatment options for this difficult-to-treat cancer population with limited therapeutic alternatives post-platinum therapy.
UK applicability
Findings from this trial would be applicable to NHS oncology practice for treatment of advanced urothelial carcinoma, provided the drug combination gains regulatory approval and fits within National Cancer Research Institute guidance and NICE appraisal frameworks for this indication.
Key measures
Overall survival, progression-free survival, objective response rate, duration of response, adverse events
Outcomes reported
The study evaluated efficacy and safety of ramucirumab combined with docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma following platinum-based chemotherapy. Primary endpoints likely included overall survival, progression-free survival, and adverse event profiles.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.